文献速递心血管MR

结合珠蛋白表型与ST段抬高型心肌梗死患者微血管阻塞的关联:一项心脏磁共振研究

Association Between Haptoglobin Phenotype and Microvascular Obstruction in Patients With STEMI: A Cardiac Magnetic Resonance Study.
PubMed 文献 · JACC Cardiovasc Imaging · 2018-04-18

该前瞻性研究纳入145例连续STEMI患者,在发病1周内行结合珠蛋白表型检测和心脏磁共振评估。多变量分析显示Hp2-2是微血管阻塞的独立预测因子(OR 5.5,95%CI 2.1–14.3,p<0.001),且可预测MVO的存在与范围(AUC均为0.63)。作者认为Hp表型可用于风险分层,并可能有助于评估减轻心肌再灌注损伤的新疗法。

要点

  • STEMI患者中Hp2-2表型占47%,其与微血管阻塞独立相关(OR 5.5)。
  • CMR显示MVO发生率26%、心肌出血8%,Hp2-2可预测MVO存在与范围(AUC 0.63)。
  • Hp表型检测或可用于STEMI风险分层,并可能用于评估新疗法。

核心结论

  • 结合珠蛋白表型是STEMI患者微血管阻塞的独立预测因子,Hp表型检测可用于风险分层,并可能有助于评估减轻心肌再灌注损伤的新疗法。

研究设计与样本

  • 前瞻性研究,连续纳入145例STEMI患者(平均年龄62.2±10.3岁,78%为男性),均在STEMI后1周内接受Hp表型检测和心脏磁共振评估;CMR用于检测LVEF、LGE瘢痕范围、微血管阻塞和心肌出血。

关键影像表现/征象

  • CMR显示危险区域占左心室质量26.6±19.1%,晚期LGE范围占左心室质量15.2±13.1%;微血管阻塞见于38例(26%),心肌出血见于12例(8%);Hp表型1-1、2-1、2-2分别见于15例(10%)、62例(43%)、68例(47%)。

诊断标准与关键数值

  • 多变量分析显示体重指数、Hp2-2、糖尿病和峰值肌钙蛋白I是MVO的独立预测因子,其中Hp2-2的OR最高(OR 5.5,95%CI 2.1–14.3,p<0.001);Hp2-2预测MVO存在的AUC为0.63(95%CI 0.53–0.72,p=0.008),预测MVO范围的AUC为0.63(95%CI 0.54–0.72,p=0.007)。

临床应用与阅片要点

  • 作者认为Hp表型是MVO的独立预测因子,Hp表型检测可用于风险分层,并可能有助于评估减轻STEMI患者心肌再灌注损伤的新疗法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to evaluate the correlation between different haptoglobin (Hp) phenotypes and myocardial infarction characteristics as detected by cardiac magnetic resonance (CMR) in consecutive patients after ST-segment elevation myocardial infarction (STEMI).

BACKGROUND: Hp is a plasma protein that prevents iron-mediated oxidative tissue damage. CMR has emerged as the gold standard technique to detect left ventricular ejection fraction (LVEF), extent of scar with late gadolinium enhancement (LGE) technique, microvascular obstruction (MVO), and myocardial hemorrhage (MH) in patients with STEMI treated by primary percutaneous coronary intervention (pPCI).

METHODS: A total of 145 consecutive STEMI patients (mean age 62.2 ± 10.3 years; 78% men) were prospectively enrolled and underwent Hp phenotyping and CMR assessment within 1 week after STEMI.

RESULTS: CMR showed an area at risk (AAR) involving 26.6 ± 19.1% of left ventricular (LV) mass with a late LGE extent of 15.2 ± 13.1% of LV mass. MVO and MH occurred in 38 (26%) and 12 (8%) patients, respectively. Hp phenotypes 1-1, 2-1, 2-2 were observed in 15 (10%), 62 (43%), and 68 (47%), respectively. Multivariable analysis demonstrated that body mass index, Hp2-2, diabetes, and peak troponin I were independent predictors of MVO with Hp2-2 associated with the highest odds ratio (OR) (OR: 5.5 [95% confidence interval [CI]: 2.1 to 14.3; p < 0.001]). Hp2-2 significantly predicted both the presence (area under the curve [AUC]: 0.63 [95% CI: 0.53 to 0.72; p = 0.008]) and extent of MVO (AUC: 0.63 [95% CI: 0.54 to 0.72; p = 0.007]).

CONCLUSIONS: Hp phenotype is an independent predictor of MVO. Therefore, Hp phenotyping could be used for risk stratification and may be useful in assessing new therapies to reduce myocardial reperfusion injury in patients with STEMI.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Pontone G, Andreini D, Guaricci AI, et al. Association Between Haptoglobin Phenotype and Microvascular Obstruction in Patients With STEMI: A Cardiac Magnetic Resonance Study. JACC Cardiovasc Imaging. 2018. PMID: 29680345. doi:10.1016/j.jcmg.2018.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。